New Evidence Reinforces Efficacy And Tolerability Of Galvus® As A New Once-daily Oral Treatment Option For Patients With Type 2 Diabetes

... New data show that Galvus® (vildagliptin), an investigational once-daily oral medicine for patients with type 2 diabetes, significantly reduced blood sugar levels in people age 65 and older - a growing group of patients with this progressive disease who can be difficult to treat with existing oral therapies1. [click link for full article] ...